New York Approves MDxHealth Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth today announced New York has certified the company's prostate cancer test, allowing MDxHealth to offer the test to residents in the state.

The company can now offer the ConfirmMDx test in all 50 states in the US. The epigenetics-based test, which was launched in May 2012, uses tissue obtained from a previous negative prostate biopsy to differentiate patients with true negative results from those who are at high risk for missed cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.